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Predictive Capacity of Risk Models in Liver 
Transplantation
Jacob D. de Boer, MD,1 Hein Putter, PhD,2 Joris J. Blok, MD, PhD,1 Ian P.J. Alwayn, MD, PhD,1  
Bart van Hoek, MD, PhD,3 and Andries E. Braat, MD, PhD1
Nearly 14 000 patients are currently on the liver trans-plantion (LT) waiting list in the United States, and each 
year >10% of these patients die without a transplantation.1 
Optimal use and allocation of livers available for transplanta-
tion are therefore essential. Such “optimal” allocation is, how-
ever, difficult to define. Currently, the majority of livers in the 
United States and Europe are allocated according to the Model 
for End-stage Liver Disease (MELD) or models derived from 
the MELD score (eg, MELD-Na).2,3 MELD is an objective 
score that includes 3 laboratory values of the recipient (creati-
nine, bilirubin, and international normalized ratio), validated 
for the prediction of 3-month waiting list  mortality.4,5 Studies 
showed that it is less suitable to accurately predict outcome 
after transplantation.6
A model to predict outcome after transplantation should 
include all relevant characteristics of the donor, the recipi-
ent, and other relevant data relating to the transplantation. It 
would enable us to objectify and quantify the impact of sev-
eral risk factors and could have numerous other applications. 
Over the past decade, several models for donor quality, recipi-
ent quality, or the combination have been developed. To pre-
dict outcome after LT, the Survival Outcomes Following Liver 
Transplantation (SOFT),6 donor MELD (D-MELD),7 and bal-
ance of risk (BAR) scores8 have been developed. While these 
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Background. Several risk models to predict outcome after liver transplantation (LT) have been developed in the last 
decade. This study compares the predictive performance of 7 risk models. Methods. Data on 62 294 deceased donor 
LTs performed in recipients ≥18 years old between January 2005 and December 2015 in the United Network for Organ 
Sharing region were used for this study. The balance of risk, donor risk index (DRI), Eurotransplant-DRI, donor-to-recipient 
model (DRM), simplified recipient risk index, Survival Outcomes Following Liver Transplantation (SOFT), and donor Model for 
End-stage Liver Disease scores were calculated, and calibration and discrimination were evaluated for patient, overall graft, 
and death-censored graft survival. Calibration was evaluated by outcome of high-risk transplantations (>80th percentile of 
the respective risk score) and discrimination by concordance index (c-index). Results. Patient survival at 3 months was 
best predicted by the SOFT (c-index: 0.68) and Balance of Risk score (c-index: 0.64), while the DRM and SOFT score had 
the highest predictive capacity at 60 months (c-index: 0.59). Overall, graft survival was best predicted by the SOFT score at 
3-month follow-up (c-index: 0.65) and by the SOFT and DRM at 60-month follow-up (c-index: 0.58). Death-censored graft 
survival at 60-month follow-up is best predicted by the DRI (c-index: 0.59) and Eurotransplant-DRI (c-index: 0.58). For patient 
and overall graft survival, high-risk transplantations were best defined by the DRM. For death-censored graft survival, this 
was best defined by the DRI. Conclusions. This study shows that models dominated by recipient factors have the best 
performance for short-term patient survival. Models that also include sufficient donor factors have better performance for 
long-term graft survival. Death-censored graft survival is best predicted by models that predominantly included donor factors.
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models incorporate donor, recipient, and transplant charac-
teristics, the donor risk index (DRI)9 and Eurotransplant-DRI 
(ET-DRI)10 include solely donor and transplant characteristics 
to measure donor and organ quality. The ET-DRI was devel-
oped and validated for the ET region in 2012. Later on, the 
simplified recipient risk index (sRRI) was developed.11 Both 
the donor model (ET-DRI) and recipient model (sRRI) were 
combined to predict outcome based on the combination of 
significant donor, transplantation, and recipient factors: the 
donor-to-recipient model (DRM).11 Although all models pre-
dict “outcome” after LT, there are several differences between 
them.12 Most importantly, the considered end point varies.
This study aims to compare the predictive capacity of 7 
models on patient-, overall graft- and death-censored graft 
survival at different posttransplant follow-up periods after LT.
MATERIALS AND METHODS
Data Selection
This study used data on LTs from January 1, 2005, until 
December 31, 2015, from the Scientific Registry of Transplant 
Recipients (SRTR). The SRTR data system includes data 
on all donors, waitlisted candidates, and transplant recipi-
ents in the United States, submitted by the members of the 
Organ Procurement and Transplantation Network (OPTN). 
The Health Resources and Services Administration, US 
Department of Health and Human Services provides over-
sight to the activities of the OPTN and SRTR contractors. 
No ethical statement was required according to European 
guidelines and Dutch law. Follow-up data were available up 
to March 2017.
Study Population
In the study period, 71 429 LTs were performed. All LTs 
in recipients <18 years old were excluded (n = 6201) as well 
as those performed with livers from living donors (n = 2347) 
and auxiliary transplanted livers (n = 37). Any combinations 
of organs other than liver and kidney were also excluded 
(n = 550). This resulted in 62 294 transplantations included in 
the analysis.
Calculation of the BAR, SOFT, DRI, DRM, D-MELD, 
and Maximum C-statistic
Variables incorporated in the respective models are 
shown in Table 1. Cold ischemic times were missing in 3% 
(n = 1562) and were singly imputed with the median cold 
ischemic time (6.3 h). Recipient body mass index was miss-
ing in 1552 cases and set at reference (body mass index <30) 
for calculation of the SOFT score. Gamma-glutamyl trans-
peptidase (GGT) and “rescue allocation” are required for 
TABLE 1.
Overview of all variables per risk model
Factor D-MELD BAR DRI ET-DRI sRRI DRM SOFT
Donor
 Age X X X X  X X
 GGT    X (NA) X (NA)  
 Race   X    
 Height   X    
 Cause of death   X X X X
 DCD   X X X  
 Partial or split   X X X  
 Serum creatinin      X
Recipient
 Age  X   X X X
 MELD score at transplantation X X  X X X
 Retransplantation  X  X X X
 Life support pretransplant  X    X
 Sex    X X  
 Etiology of disease    X X  
 BMI      X
 Encephalopathy pretransplant      X
 Portal vein thrombosis      X
 Portal bleed within 48 h pretransplant      X
 Previous abdominal surgery      X
 Ascites pretransplant      X
 Dialysis pretransplant      X
 Pretransplant status (IC, hospital, home)      X
 Albumin      X
Transplant
 Location (local, regional, national)   X X  X X
 Cold ischemia time  X X X  X X
 Rescue allocation    X (NA)  X (NA)  
Number of factors 2 6 8 8  13 18
BAR, balance of risk score; BMI, body mass index; DCD, donation after circulatory death; D-MELD, donor age and preoperative Model for End-stage Liver Disease; DRI, donor risk index; DRM, donor-
to-recipient model; ET-DRI, Eurotransplant donor risk index; IC: intensive care department; GGT, gamma-glutamyl transpeptidase; MELD, Model for End-stage Liver Disease; NA, not applicable; SOFT, 
Survival Outcomes Following Liver Transplantation score; sRRI, simplified recipient risk index.
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calculation of the ET-DRI10 but were not available in the 
dataset. Rescue allocation can be considered a fast-track 
allocation that is used in the ET region for a “center-ori-
ented” allocation after organs have not been accepted in 
“patient-oriented” allocation for medical or logistical rea-
sons.13 They were therefore set at reference (GGT <50 U/L 
and rescue allocation “no”). Then, BAR score, SOFT score, 
DRI, ET-DRI, sRRI, DRM, and D-MELD scores were cal-
culated for all transplantations as described before.6-11 The 
maximal c-statistic was calculated for a dynamic model 
including all factors that were incorporated in either the 
BAR, SOFT, DRI, ET-DRI, sRRI, DRM, or D-MELD score. 
The model is considered dynamic because the effects of each 
factor were estimated for each time point (per month fol-
low-up period) separately.
Definitions
Primary outcomes were (1) patient, (2) overall graft, and 
(3) death-censored graft survival at follow-up periods of 
3 months, 1 year, and 5 years after transplantation. Patient 
survival (1) was defined as the time period between trans-
plantation and patient death. Overall graft survival (2) was 
evaluated as nondeath-censored graft survival and was defined 
as the time period between transplantation and either date of 
graft failure or patient death, whichever occurred first. Death-
censored graft survival (3) was defined as the time period 
between transplantation and date of graft failure (note that 
patients were censored when deceased). Graft failure was, 
as specified in the OPTN follow-up forms, not entered for 
patients who died as a result of some other factor unrelated 
to graft failure. The individual scores were used to define risk 
groups of transplantations using increments of 20% in the 
quantiles of risk scores. High-risk transplantations were arbi-
trarily defined as scores above the 80th percentile according 
to the respective risk models.
Statistical Analysis
Clinical characteristics were summarized by median and 
25% and 75% interquartile ranges (IQR) and number and 
percentage (N/%) for, respectively, continuous and categori-
cal variables. Numerical and categorical factors between 
groups were compared using Kruskall–Wallis and Chi-
square tests. Predictive performance of all models was com-
pared by the area under the ROC curve or “c-statistic.”14 
This c-statistic was calculated monthly up to 5 years for 
all 3 considered end points. Calculated c-statistics of indi-
vidual models were compared in a boot-strapped 1000-fold 
database. Subsequently, transplantations were stratified by 
risk groups per score to evaluate the discriminative ability. 
Outcome of transplantations was stratified by risk groups 
using increments of 20% in the quantiles of risk scores in 
Kaplan–Meier analyses. Survival rate and rate of graft loss in 
the high-risk transplantations (above 80th percentile) were 
compared per end point between the several scores at 5-year 
follow-up. For death-censored graft survival, censoring by 
death was accounted for as a competing risk when calculat-
ing cumulative incidences.15
All analyses were performed with SPSS version 24 and R 
version 3.3.2. A P value below 0.05 was considered statisti-
cally significant. All analyses were performed in collaboration 




In the study period, 62 294 performed LTs were included. 
Mean transplant follow-up was 5.5 years for patient sur-
vival. Demographics of donors, patients, and transplantations 
are shown in Table  2. Most notably, donors had a median 
age of 42 years old (IQR: 26–54) and were transplanted 
with a median cold ischemic time of 6.3 hours (IQR: 5–8). 
Approximately 10% of all donors had diabetes mellitus, and 
about a third of all livers were shared either regionally (24%) 
or nationally (5%). Recipients had a median age of 56 years 
old and a median laboratory MELD score of 21 (IQR: 14–
30). Most recipients were transplanted for hepatitis C–related 
disease (28%), followed by alcoholic cirrhosis (20%) or other 
causes of cirrhosis (17%).
Discrimination
For the BAR, ET-DRI, DRI, DRM, sRRI, SOFT, and 
D-MELD scores, the change in predictive capacity (c-index) 
is demonstrated over time and per outcome type. For patient 
survival, this is shown in Figure 1A. In general, the ability to 
predict outcomes accurately decreases over time. Therefore, 
outcome at short-term follow-up can be more accurately pre-
dicted than at longer follow-up. Patient survival at 3-month 
follow-up was best predicted by the SOFT score (c-index: 0.68, 
P < 0.001) followed by the BAR (c-index: 0.64, P < 0.001) and 
DRM scores (c-index: 0.61, P < 0.001). From 3-year follow-
up onward, the SOFT score has a comparable performance 
to the DRM. The initial high performance of the BAR score 
decreases rapidly to below 0.6 at 18-month follow-up. Patient 
survival at 60-month follow-up was best predicted by the 
DRM and SOFT score (c-index: 0.59 for both, P = 0.60). The 
maximal c-statistic for patient survival was higher at each 
time period than all other models (P < 0.001). The model with 
all factors included, calibrated monthly, reached a c-statistic 
of 0.70 at 3-month follow-up and decreased gradually to 0.66 
and 0.63 at 12- and 60-month follow-up, respectively.
To predict overall graft survival at short-term follow-up, 
the highest predictive value at 3 months was also achieved 
by the SOFT score (c-index: 0.65, P < 0.001), as is shown in 
Figure 1B. The BAR score and DRM performed reasonably 
when predicting overall graft survival at 3-month follow-
up with c-indexes of 0.61 and 0.59, P ≤ 0.001, respectively. 
Overall graft survival at 60-month follow-up was again best 
predicted by the SOFT score and by the DRM with a simi-
lar c-index of 0.58 (P = 0.22). A notable difference between 
these 2 models is the performance at short term; the SOFT 
score had an optimal performance at approximately 2 months 
posttransplantation, whereas the DRM reached a peak after 6 
months. Performance of the other risk scores for overall graft 
survival stabilized around a c-index of 0.56 after approxi-
mately 2 years. The maximal c-statistic for overall graft sur-
vival was 0.67 at 3-month follow-up and decreased to 0.65 
and 0.62 at 12- and 60-month follow-up, respectively. These 
c-statistics were significantly higher than all other models at 
3-, 12-, and 60-month follow-up (P < 0.001).
Death-censored graft survival showed a different picture; 
models that are dominated by donor factors like the DRI as 
well as the ET-DRI had best predictive capability as from 1 
year onward, as shown in Figure 1C. The DRI and ET-DRI 
achieved c-indexes at 12 months of 0.60 and 0.59 (P = 0.01), 
respectively, and at 60 months of 0.59 and 0.58 (P = 0.16). 
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The maximal c-statistic for death-censored graft survival was 
significantly higher as compared with each other model at the 
respective time points (P < 0.001); it varied from 0.68 to 0.66 
and 0.65 at 3-, 12-, and 60-month follow-up, respectively.
Calibration
As a measure of calibration, outcome of transplantations 
was stratified by risk groups defined by increments of 20% of 
the several risk models (Table 3). The lowest patient survival 
rate in high-risk transplantations was observed in the group 
defined by the DRM with a survival rate of 64% at 5-year 
follow-up (Figure 2). Patient survival stratified by other risk 
models is shown in Figure S1A–F, SDC, http://links.lww.com/
TXD/A209. Also, for overall graft survival, the lowest sur-
vival rate in high-risk transplantations was observed in the 
group defined by the DRM (Figure 3) and by the SOFT score 
with a survival rate of 62% (Figure 4). Overall graft survival 
stratified by other risk models is shown in Figure S2A–E, 
SDC, http://links.lww.com/TXD/A209. Death-censored graft 
survival was best predicted by models that were dominated by 
donor characteristics, such as the DRI and ET-DRI. In high-
risk transplantations defined by these models, a graft loss rate 
of 15% was observed (Figures 5 and 6). Death-censored graft 
survival stratified by other risk models is shown in Figure 
S3A–E, SDC, http://links.lww.com/TXD/A209.
DISCUSSION
Predicting outcome after LT is important for issues vary-
ing from quality control to decision-making for liver offers. It 
could even be important for improving allocation algorithms. 
Therefore, several prediction models have been proposed in 
TABLE 2.
Study demographics (n = 62 294).
Donor factor Mean Median IQR
Age (y) 41 42 (26–54)
Height (cm) 171 173 (165–180)
Weight (kg) 80 78 (67–91)
BMI 27 26 (23–30)
Cold ischemic time 6.8 6.3 (5–8)
 N %  
Sex (male) 37 202 60%  
Donortype (DCD) 3262 5%  
Cause of death
 Anoxia 14 452 23%  
 CVA/stroke 24 226 39%  
 Head trauma 22 036 35%  
 CNS tumor 327 1%  
 Other 1253 2%  
Donor race
 White 49 078 79  
 Black 11 232 18  
 Other 1984 3  
Split (yes) 788 1  
Share
 Local 44 402 71  
 Regional 14 968 24  
 National 2924 5  
Diabetes
 0–5 y 2445 4  
 6–10 y 1242 2  
 >10 y 2400 4  
 Yes, duration unknown 701 1  
 No or unknown 55 506 89  
Recipient factor Mean Median IQR
 Age (y) 54 56 50–61
 Height (cm) 172 173 165–180
 Weight (kg) 84 82 70–96
 BMI 28 28 24–32
 Laboratory MELD 22 21 14–30
 N %  
Sex (Male) 41 968 67  
Primary disease
 Metabolic 1331 2%  
 Acute 2795 5%  
  Cholestatic 4695 8%  
 Alcoholic 12 514 20%  
 Malignant 7006 11%  
 HBV 1673 3%  
 HCV 17 696 28%  
 Other cirrhosis 10 590 17%  
  Other/unknown 3994 6%  
Race (SRTR)
 Asian 2810 5%  
 Black 6264 10%  
 White 52 468 84%  
 Other 752 1%  
Pretransplant life support (yes) 5102 8%  
Ever approved for HCC  
exception (yes)
16 764 27%  
Retransplantation (yes) 4080 7%  
Last encephalopathy
 Grade 1–2 32 586 52%  
 Grade 3–4 7365 12%  
 Previous upper abdominal  
surgery (yes)
24 241 39%  
 History of portal vein  
thrombosis (yes)
2733 4%  
Diabetes type (present)
 1 1442 2%  
 2 12 418 20%  
 Other 160 0.3%  
 Type unknown 2625 4%  
Risk scores Mean Median IQR
 DRI 1.4 1.3 (1.1–1.6)
 sRRI 2.4 2.2 (1.8–2.6)
 ET-DRI 1.3 1.3 (1.0–1.5)
 DRM 2.8 2.6 (2.1–3.4)
 SOFT score 9.4 7.0 (4–13)
 D-MELD score 901 782 (480–1218)
 BAR score 8.9 8 (4–13)
BAR, balance of risk score; BMI, body mass index; CNS, central nervous system; CVA, cerebrovas-
cular accident; DCD, donation after circulatory death; DRI, donor risk index; DRM, donor-to-recipient 
model; ET-DRI, Eurotransplant donor risk index; GGT, gamma-glutamyl transpeptidase; HBV, hepatitis 
B virus; HCC, hepatocellular carcinoma; HCV, hepatitis C virus; IQR, interquartile range; MELD, Model 
for End-Stage Liver Disease; SOFT, Survival Outcomes Following Liver Transplantation score; sRRI, 
simplified recipient risk index; SRTR, Scientific Registry of Transplant Recipients.
TABLE 2. (Continue d)
Study demographics (n = 62 294).
Donor factor Mean Median IQR
Continued next page
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the past decade. This study has evaluated their performance 
with SRTR data, when applied to patient-, overall graft-, 
and death-censored graft survival at different posttransplant 
follow-up periods. Our results show that models that predom-
inantly constitute of recipient characteristics have the  best 





3 months 1 year 5 years
BAR 0.64 0.61 0.56
ETDRI 0.54 0.55 0.54
DRI 0.55 0.55 0.55
DRM 0.61 0.61
0.59, P < 0.001
(P = 0.794 vs
DRM)
sRRI 0.60 0.60 0.57
SOFT 0.68, significanceof: P <0.001
0.63,
P <0.001 0.59
DMELD 0.60 0.58 0.56
C-maximum 0.70 0.66 0.63
Overall graft survival
3 months 1 year 5 years
BAR 0.61 0.59 0.55
ETDRI 0.55 0.56 0.54
DRI 0.57 0.57 0.56
DRM 0.59 0.59 0.58





(P = 0.218 vs DRM)
DMELD 0.58 0.57 0.55
C-maximum 0.67 0.65 0.62
Death-censored graft survival
3 months 1 year 5 years
BAR 0.56 0.54 0.53
ETDRI 0.58 0.59 0.58
DRI 0.59
0.60, P <0.001\
(P = 0.126 vs SOFT,
P = 0.006 vs ET-DRI)
0.59, P <0.001
(P = 0.158 vs ET-DRI)
DRM 0.56 0.57 0.56
sRRI 0.53 0.54 0.54
SOFT 0.61, P <0.001,(P = 0.034 vs DRI) 0.59 0.57
DMELD 0.55 0.56 0.55
C-maximum 0.68 0.66 0.65
FIGURE 1. Performance of risk models. A, Patient survival. B, Overall graft survival. C, Death-censored graft survival. BAR, balance of risk 
score; D-MELD, donor age and preoperative Model for End-Stage Liver Disease; DRI, donor risk index; DRM, donor-to-recipient model; ET-DRI, 
Eurotransplant donor risk index; SOFT, Survival Outcomes Following Liver Transplantation score; sRRI, simplified recipient risk index.
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Models that include a combination of donor and recipient 
characteristics, like the SOFT and DRM, have a better per-
formance for predicting overall graft survival. Death-censored 
graft survival is best predicted by a model that predominantly 
constitutes of donor factors, as in the DRI and ET-DRI.
To evaluate the efficacy of LT, overall graft survival might 
be the most suitable outcome measure. This end point cov-
ers patient mortality as well as survival of the graft, which is 
as important in the light of the current organ shortage. Both 
the DRM and SOFT scores, which include donor and recipi-
ent characteristics, have the highest predictive value for this 
outcome at long-term follow-up (c-index: 0.60). However, 
the highest overall predictive performance was observed for 
short-term patient survival. Both the SOFT and BAR scores 
achieved c-indexes of 0.68 and 0.64, respectively, for predict-
ing patient survival at 3-month follow-up.
Our results show that when the follow-up period increases, 
the accuracy of the prediction of posttransplant outcome 
decreases. This increasing uncertainty is most likely the result 
of the input for the models; the prediction is based on factors 
that are defined at the time of or just before the transplan-
tation. The initial strong relation with short-term complica-
tions or early mortality after transplantation decreases rapidly 
after the transplantation. Issues like changes in therapy, unex-
pected events, or medical compliance are therefore not taken 
into account. Models that predict short-term outcomes are 
TABLE 3.
Outcome by risk groups at 5-year follow-up
Patient survival (%) N at risk Overall graft survival (%) N at risk Graft loss (%) N at risk
DRI
 <20% 77.7 5432 76.4 5320 6.9 5320
 20%–40% 76.5 5085 74.7 4943 8.3 4943
 40%–60% 72.9 4839 70.5 4655 10.2 4655
 60%–80% 71.0 4801 68.0 4557 12.3 4557
>80% 68.2 4841 63.7 4462 14.9 4462
sRRI
 <20% 78.8 5736 75.1 5434 10.3 5434
 20%–40% 76.2 5219 73.6 5000 9.3 5000
 40%–60% 73.8 5146 71.3 4933 9.8 4933
 60%–80% 71.5 4876 68.9 4677 11.4 4677
>80% 66.0 4021 64.3 3893 11.7 3893
ET-DRI
 <20% 77.5 5529 75.9 5394 7.5 5394
 20%–40% 76.4 4724 74.7 4590 7.7 4590
 40%–60% 73.4 5100 71.2 4922 10.3 4922
 60%–80% 70.6 4774 67.3 4522 12.4 4522
 >80% 68.6 4871 64.4 4509 14.5 4509
DRM
 <20% 80.1 5813 77.4 5585 8.5 5585
 20%–40% 76.4 5227 73.5 4984 9.7 4984
 40%–60% 74.8 5107 72.2 4897 9.5 4897
 60%–80% 71.1 4728 68.6 4540 11.2 4540
 >80% 63.8 4123 61.5 3931 13.7 3931
SOFT
 <20% 77.7 4297 75.4 4139 8.6 4139
 20%–40% 76.7 4958 73.9 4744 9.3 4744
 40%–60% 75.6 4987 72.7 4760 10.1 4760
 60%–80% 73.2 6468 70.5 6190 10.9 6190
 >80% 64.5 4288 62.1 4104 13.1 4104
BAR
 <20% 77.0 3461 74.3 3319 9.3 3319
 20%–40% 73.5 5711 71.0 5474 10.0 5474
 40%–60% 75.9 6748 72.5 6401 11.2 6401
 60%–80% 73.7 4648 71.3 4465 10.4 4465
 >80% 67.7 4430 65.8 4278 11.1 4278
D-MELD
 <20% 76.8 5225 74.8 5071 8.0 5071
 20%–40% 75.2 5357 72.6 5144 9.8 5144
 40%–60% 74.5 5164 71.9 4942 10.4 4942
 60%–80% 72.6 4992 69.4 4728 11.7 4728
 >80% 67.3 4260 64.6 4052 12.6 4052
Values in bold indicate the highest rate per outcome.
BAR, balance of risk score; D-MELD, donor age and preoperative Model for End-stage Liver Disease; DRI, donor risk index; DRM, donor-to-recipient model; ET-DRI, Eurotransplant donor risk index; 
sRRI, simplified recipient risk index; SRTR, Scientific Registry of Transplants Recipients.
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therefore more likely to achieve higher c-indexes as compared 
with models that focus on long-term survival.16 Our results 
also show that the performance of posttransplant outcome 
decreases when used for other end  points than they were 
developed for. This applies to the respective outcome as well 
as the considered follow-up period.
The maximal c-indexes that can be achieved by incorpo-
rating all factors of the respective models are promising and 
indicate that current models may be further improved. It is to 
be noted that in these maximum models, the effects of each 
factor are calibrated for each time point separately. The SRTR 
has made an effort to do so by analyzing their entire dataset 
and all variables.17 They have developed models for patient 
and overall graft survival at 1- and 3-year follow-up. These 
4 models include between 40 and 48 factors and incorporate 
between 165 and 204 coefficients.17 They are updated peri-
odically and can be used to correct center-specific outcomes.18 
Although the extent of the data and analyses are impressive, 
FIGURE 2. Patient survival by DRM risk groups, Kaplan–Meier analysis. DRM, donor-to-recipient model.
FIGURE 3. Overall graft survival by SOFT risk groups, Kaplan–Meier analysis. SOFT, Survival Outcomes Following Liver Transplantation score.
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the number of coefficients and the required data pose chal-
lenges for other transplant organizations to use them. The 
1-year SRTR models for patient and graft survival in adults 
achieved c-indexes at 1-year follow-up of 0.677 and 0.664, 
respectively (data SRTR).19
Our results are in line with published results on the per-
formance of all models when they are applied to their initial 
end points. For patient survival at 90-day follow-up, the SOFT 
score has a reported predictive capacity of 0.76,8 (c-index 
of 0.68 in this study) and the BAR score of 0.66–0.748,20-
25 (c-index of 0.64 in this study). In one study, a c-index of 
0.8 was reported for both the BAR and SOFT scores.26 The 
D-MELD was also developed for patient survival. It has a rela-
tively low reported predictive capacity, most likely because of 
its simplicity and because it is often applied to short-term out-
comes.8,23,24,27-29 To predict graft survival at long-term follow-
up, the DRM model has been developed in the ET region. It 
has a reported c-index of 0.62 to predict 5-year graft survival11 
FIGURE 4. Overall graft survival by DRM risk groups, Kaplan–Meier analysis. DRM, donor-to-recipient model.
FIGURE 5. Death-censored graft survival by DRI risk groups, Kaplan–Meier analysis. DRI, donor risk index.
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in the ET database (c-index of 0.58 in this study). In calculat-
ing the DRM, GGT and rescue allocation were not available 
and were therefore set at reference in this study. Most likely 
the c-index would be higher if these factors had been available 
to get a more accurate DRM value. Models that solely include 
donor factors like the ET-DRI and DRI provide a suboptimal 
predictive capacity for long-term overall graft survival when 
used without adjustment for recipient characteristics as indi-
cated by a c-index below 0.6.8,23,24,30-32 These models, however, 
have the best performance for predicting death-censored graft 
survival. Such donor models can therefore be considered as a 
measure for the quality of the organ itself.
We have chosen to validate the risk models in the United 
Network for Organ Sharing database, because it is the 
most complete and extensive database available. Therefore, 
most risk models could be calculated correctly, except for 
the ET-DRI. The ET-DRI, also used for the DRM, contains 
2 factors (rescue allocation and GGT) that were not avail-
able. While most studies focus on patient survival at short-
term follow-up, this study has analyzed patient, overall, and 
death-censored graft survival with the follow-up period as a 
continuous variable. The findings from this study, an objec-
tive comparison of models in a large dataset, may be used as a 
reference to choose an appropriate model.
In comparing center-specific outcomes, risk models may 
be used to take potential differences in donor and recipient 
characteristics (case-mix) into account.18,33 When outcomes 
of individual transplant centers are not adjusted for donor 
quality, available “high-risk” liver allografts are likely less 
used. Effects of a focus on absolute outcomes seems to be 
already more present in the United States than in Europe; 
although utilization rates of available livers seem to be simi-
lar between both, the quality of transplanted livers is not.34-36 
European transplant centers tend to accept livers that have 
a higher mean donor age and have more comorbidities on 
average.37,38
Besides an application in evaluating center-specific out-
comes, risk models could also have a great value for improv-
ing allocation algorithms. The modest discriminative accuracy 
of risk prediction models is currently the most important 
concern.22,39 It is important to note that c-statistics represent 
the accuracy of a model to predict in what order individual 
patients will experience an event. Models may therefore have 
limited use for individual patients but might define risk fac-
tor strata very well. Such findings have been published for 
the widely used Gail model for breast cancer. It is reported 
to have a modest discriminatory accuracy (c-index: 0.58) but 
a good fit in the dataset.40,41 Currently, liver allocation in the 
United States and Europe is performed using the (Na-)MELD 
score.3 This algorithm does not take into account outcome 
after transplantation. Models for outcome after LT could 
therefore increase the overall survival benefit42 by balancing 
the estimated posttransplantation outcome with the expected 
outcome on the waiting list by the MELD score.43 For LT, 
the risk models may not be perfect, but they might represent 
the most accurate objective prediction of outcome that is 
currently available. Therefore, incorporating estimated sur-
vival at 3-month follow-up (with a c-statistic over 0.7) might 
provide a good start. We should, however, strive to further 
improve the performance of these models. This might be done 
by including more direct (bio) data. Such data may become 
available with the introduction of machine perfusion.20,44 
Also, a more detailed characterization of patients may be 
incorporated, for example, by including the frailty index or 
the degree of sarcopenia.45-48
CONCLUSIONS
This study has validated the performance of 7 risk models 
in the perspective of different LT end points. The accuracy of 
predicting posttransplant outcome decreases when the follow-up 
period increases. Models dominated by recipient variables have 
FIGURE 6. Death-censored graft survival by ET-DRI risk groups, Kaplan–Meier analysis. ET-DRI, Eurotransplant donor risk index.
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the best performance for predicting short-term patient survival. 
Overall graft survival is best predicted by the DRM and SOFT 
scores, models that combine donor and recipient characteristics. 
The DRI and ET-DRI best predict death-censored graft survival 
and can therefore best describe donor quality.
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